Protalix Ltd.

Famewave Ltd.

Ccam Biotherapeutics Ltd.

Biond Biologies Ltd.

Tehila Ben-Moshe

Avidor Shulman

Yair Sapir

Ilana Mandel

Yoseph Shaaltiel

Tali Kizhner

Ilya Ruderfer

Talia Shekhter

Yaniv Azulay

Timothy David Jones

Gal Markel

Jacob Schachter

Rona Ortenberg

Robert George E Holgate

Francis Joseph Carr

Francis J Carr

Ayala Lewkowicz

Dana Haves Ziv

Motti Hakim

Dror Alishekevitz

Anna Fridman-Dror

Ilana Goldshtein

Tsuri Peretz

Edna Meilin

Ilana Mande

Yossi Gottfried

Rotem Faygenboim-Ornai

Orit Shilovitzky

Rozi Ravit Uzan Gueta

Lilach Chen Zeltsburg

Robert George Holgate

Orit Shilovittzky

Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.

Stabilized alpha-galactosidase and uses thereof

Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.

Humanized antibodies against CEACAM1

Polynucleotides encoding humanized antibodies against CEACAM1

The present invention provides monoclonal antibodies, or antigen-binding portions thereof, against ILT2, as well as pharmaceutical compositions comprising same and methods of producing same. Also provided are methods of treating cancer comprising administering the antibodies or compositions of the invention. Methods of treating cancer, combination treatments, and patient selection are also provided.

Antibodies against ILT2

Stabilized &#x3b1;-galactosidase and uses thereof

The present invention provides compositions comprising anti-CEACAM1 antibodies, compositions comprising antibodies capable of inhibiting or blocking the interaction between PD-1 and its ligands, and methods for their combined use in treating cancer.

Compositions comprising anti-CEACAM1 and anti-PD antibodies for cancer therapy

Growing community of inventors

Koranit, Israel

Tehila Ben-Moshe